全球胜肽药物偶联物市场2023-2030

预计全球胜肽药物缀合物市场在预测期（2023-2030年）将以9.4%的CAGR成长。此市场归因于癌症和代谢紊乱盛行率上升、新药研发投资增加以及药物开发技术进步等因素。根据 Globocan 2020，癌症病例数为 50,550,287 例。其中，全球新增病例总数19,292,789例。

细分市场前景

全球胜肽药物偶联物市场按类型和产品细分。根据类型，市场分为诊断和治疗。根据产品，市场细分为 Melflufen、Lutetium、ANG1005、BT1718 和 CBX-12。在这一类型中，由于新兴的标靶治疗药物具有增强的肿瘤渗透性和选择性，因此预计治疗细分市场将占据相当大的市场份额。

预计 Melflufen 细分市场将在全球胜肽药物偶联物市场中占据相当大的份额

其中，melflufen细分市场预计将在全球胜肽药物偶联物市场中占据相当大的份额。此细分市场的成长归因于人们对当前治疗选择的认识不断提高、有利的报销政策、Melflufen 的推出以及PDC 药物在癌症治疗中的快速应用。2021 年2 月，FDA 批准了第一个抗癌胜肽药物结合物，美法崙氟芬酰胺或美氟芬，与地塞米松合併使用。基于2期HORIZON研究，该产品由瑞典生物技术公司Oncopeptides AB开发，获得加速批准。患有难治性多发性骨髓瘤的成年患者，曾经接受过至少 4 种治疗，且其疾病对至少 1 种蛋白酶体抑制剂、1 种免疫调节剂和 1 种 CD38 定向单株抗体难以治疗。

区域展望

全球胜肽药物偶联物市场根据地理位置进一步细分，包括北美（美国和加拿大）、欧洲（英国、义大利、西班牙、德国、法国和欧洲其他地区）、亚太地区（印度、中国、日本、韩国和亚洲其他地区）以及世界其他地区（中东和非洲以及拉丁美洲）。其中，由于开发和商业化新输送系统的投资不断增加，预计亚太地区将在全球市场中占据显着份额。

北美地区预计全球胜肽药物偶联物市场将以显着的CAGR成长

在所有地区中，北美地区预计在预测期内将以相当大的CAGR成长。推动北美市场的主要因素是该地区癌症病例数量的增加，预计这肯定会影响未来几年胜肽药物缀合物市场的成长。根据美国癌症协会 (ACS) 的数据，2022 年，美国报告了约 1,918,030 例新癌症病例和 609,360 例癌症死亡病例。根据英国皇家学会出版组织报道，HPRP-A1-TAT是一种杂合胜肽，能破坏细胞膜，导致细胞质内容物快速渗漏，具有很强的抗癌活性。

市场参与者展望

服务全球胜肽药物缀合物市场的主要公司包括： Angiochem Inc.、Bicycle Therapeutics, Inc.、Cybrexa Therapeutics Inc.、Novartis AG、Oncopeptides AB 等。市场参与者透过各种策略（包括併购、合作、合作、融资和新产品发布），为市场成长做出了巨大贡献，以保持市场竞争力。例如，2023 年 9 月，总部位于日本神奈川的生物製药上市公司 PeptiDream Inc. 与罗氏集团旗下美国基因泰克公司签订了一项新的多目标合作和许可协议，旨在发现和开发新型大环肽-放射性同位素药物缀合物。

报告涵盖：

• 2022年市场价​​值资料分析及2030年预测。
• 每个细分市场的年化市场收入（百万美元）。
• 主要地理区域的国家分析。
• 全球胜肽药物偶联物市场的主要公司。根据现有资料，报告中还提供了与新产品发布相关的资讯以及相关新闻。
• 透过确定未来强劲成长的关键细分市场来分析业务策略。
• 市场进入和市场扩张策略分析。
• 透过识别市场中「谁的立场」来制定竞争策略。

目录

第 1 章：报告摘要

• 目前行业分析及成长潜力展望
• 研究方法和工具
• 市场区隔
  • 按细分
  • 按地区

第 2 章：市场概述与见解

• 报告范围
• 分析师见解和当前市场趋势
  • 主要发现
  • 建议
  • 结论

第 3 章：竞争格局

• 主要公司分析
• Angiochem Inc.
  • 概述
  • 财务分析
  • SWOT分析
  • 最近的发展
• Bicycle Therapeutics, Inc.
  • 概述
  • 财务分析
  • SWOT分析
  • 最近的发展
• Cybrexa Therapeutics Inc.
  • 概述
  • 财务分析
  • SWOT分析
  • 最近的发展
• Novartis AG
  • 概述
  • 财务分析
  • SWOT分析
  • 最近的发展
• Oncopeptides AB
  • 概述
  • 财务分析
  • SWOT分析
  • 最近的发展
• 关键策略分析

第 4 章：市场细分

• 全球胜肽药物偶联物市场（按类型）
  • 诊断
  • 治疗性
• 全球胜肽药物偶联物市场（按产品）
  • 梅尔氟芬
  • 铔
  • ANG1005
  • BT1718
  • CBX-12

第 5 章：区域分析

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 英国
  • 德国
  • 义大利
  • 西班牙
  • 法国
  • 欧洲其他地区
• 亚太
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 世界其他地区

第 6 章：公司简介

• AstraZeneca co.
• Camurus AB
• Chiasma, Inc.
• CRINETICS PHARMACEUTICALS
• Dauntless Pharmaceuticals
• Ipsen Biopharmaceuticals, Inc.
• Midatech Pharma PLC
• PeptiDream Inc.
• Peptron, Inc.
• Pfizer Inc.,
• Soricimed Biopharma
• Teva Pharmaceuticals Inc.
• Theratechnologies Inc.
• Validus Pharmaceuticals LLC
• WuXi AppTec Co., Ltd.

Title: Global Peptide Drug Conjugates Market Size, Share & Trends Analysis Report by Type (Diagnostic and Therapeutic), and by Product (Melflufen, Lutetium, ANG1005, BT1718 and CBX-12),Forecast Period (2023-2030).

The global peptide drug conjugates market is anticipated to grow at a CAGR of 9.4% during the Forecast Period (2023-2030). The market is attributed to factors including the increasing prevalence of cancer and metabolic disorders, rising investments in the R&D of novel drugs, and technological advancements in drug development. According to the Globocan 2020, number of cancer cases were 50,550,287. Of which, the total number of new cases 19,292,789 around the globe.

Segmental Outlook

The global peptide drug conjugates market is segmented on the type, and product. Based on the type, the market is sub-segmented into diagnostic and therapeutic. Based on the product, the market is sub-segmented into melflufen, lutetium, ANG1005, BT1718 and CBX-12. Among the type, the therapeutic sub-segment is anticipated to hold a considerable share of the market, owing to the emerging targeted therapeutic that present increased tumor penetration and selectivity.

The Melflufen Sub-Segment is Anticipated to Hold a Considerable Share of the Global Peptide Drug Conjugates Market

Among the product, the melflufen sub-segment is expected to hold a considerable share of the global Peptide Drug Conjugates market. The segmental growth is attributed to the owing to increasing awareness about current treatment options, favorable reimbursement policies, the launch of Melflufen and rapid uptake of PDC drugs in cancer therapy., In February 2021, the FDA approved the first anticancer peptide-drug conjugate, melphalan flufenamide, or melflufen, for use in combination with dexamethasone. Based on the phase 2 HORIZON research, the product, developed by the Swedish biotech company Oncopeptides AB, received accelerated approval. In adult patients with refractory multiple myeloma, who have received at least 4 prior lines of therapy and whose disease is refractory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 CD38-directed monoclonal antibody.

Regional Outlook

The global peptide drug conjugates market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia-Pacific is anticipated to hold a prominent share of the market across the globe, owing to the rising investments to develop and commercialize new delivery systems.

The North America Region is Expected to Grow at a Significant CAGR in the Global Peptide Drug Conjugates Market

Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. The major factors driving the North America market is the increasing number of cancer cases across the region is estimated to certainly impact the peptide drug conjugates market growth in upcoming years. According to the American Cancer Society (ACS), in 2022, around 1,918,030 new cancer cases and 609,360 cancer mortalities were reported in the US. As per the reports of Royal Society Publishing Organization, HPRP-A1-TAT, a hybrid peptide, can destroy the cell membrane to cause rapid leakage of cytoplasmic contents, and has a strong anti-cancer activity.

Market Players Outlook

The major companies serving the global peptide drug conjugates market include: Angiochem Inc., Bicycle Therapeutics, Inc., Cybrexa Therapeutics Inc., Novartis AG, Oncopeptides AB, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in September 2023, PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company entered into a new multi-target collaboration and license agreement with US based Genentech, a member of the Roche Group, targeted on the discovery and development of novel macrocyclic peptide-radioisotope drug conjugates.

The Report Covers:

• Market value data analysis of 2022 and forecast to 2030.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global peptide drug conjugates market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

• Current Industry Analysis and Growth Potential Outlook
• 1.1. Research Methods and Tools
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. By Region

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Findings
  • 2.2.2. Recommendations
  • 2.2.3. Conclusion

3. Competitive Landscape

• 3.1. Key Company Analysis
• 3.2. Angiochem Inc.
  • 3.2.1. Overview
  • 3.2.2. Financial Analysis
  • 3.2.3. SWOT Analysis
  • 3.2.4. Recent Developments
• 3.3. Bicycle Therapeutics, Inc.
  • 3.3.1. Overview
  • 3.3.2. Financial Analysis
  • 3.3.3. SWOT Analysis
  • 3.3.4. Recent Developments
• 3.4. Cybrexa Therapeutics Inc.
  • 3.4.1. Overview
  • 3.4.2. Financial Analysis
  • 3.4.3. SWOT Analysis
  • 3.4.4. Recent Developments
• 3.5. Novartis AG
  • 3.5.1. Overview
  • 3.5.2. Financial Analysis
  • 3.5.3. SWOT Analysis
  • 3.5.4. Recent Developments
• 3.6. Oncopeptides AB
  • 3.6.1. Overview
  • 3.6.2. Financial Analysis
  • 3.6.3. SWOT Analysis
  • 3.6.4. Recent Developments
• 3.7. Key Strategy Analysis

4. Market Segmentation

• 4.1. Global Peptide Drug Conjugates Market by Type
  • 4.1.1. Diagnostic
  • 4.1.2. Therapeutic
• 4.2. Global Peptide Drug Conjugates Market by Product
  • 4.2.1. Melflufen
  • 4.2.2. Lutetium
  • 4.2.3. ANG1005
  • 4.2.4. BT1718
  • 4.2.5. CBX-12

5. Regional Analysis

• 5.1. North America
  • 5.1.1. United States
  • 5.1.2. Canada
• 5.2. Europe
  • 5.2.1. UK
  • 5.2.2. Germany
  • 5.2.3. Italy
  • 5.2.4. Spain
  • 5.2.5. France
  • 5.2.6. Rest of Europe
• 5.3. Asia-Pacific
  • 5.3.1. China
  • 5.3.2. India
  • 5.3.3. Japan
  • 5.3.4. South Korea
  • 5.3.5. Rest of Asia-Pacific
• 5.4. Rest of the World

6. Company Profiles

• 6.1. AstraZeneca co.
• 6.2. Camurus AB
• 6.3. Chiasma, Inc.
• 6.4. CRINETICS PHARMACEUTICALS
• 6.5. Dauntless Pharmaceuticals
• 6.6. Ipsen Biopharmaceuticals, Inc.
• 6.7. Midatech Pharma PLC
• 6.8. PeptiDream Inc.
• 6.9. Peptron, Inc.
• 6.10. Pfizer Inc.,
• 6.11. Soricimed Biopharma
• 6.12. Teva Pharmaceuticals Inc.
• 6.13. Theratechnologies Inc.
• 6.14. Validus Pharmaceuticals LLC
• 6.15. WuXi AppTec Co., Ltd.

LIST OF TABLES

• 1. GLOBAL PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
• 2. GLOBAL DIAGNOSTIC PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 3. GLOBAL THERAPEUTIC PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 4. GLOBAL PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
• 5. GLOBAL MELFLUFEN PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 6. GLOBAL LUTETIUM PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 7. GLOBAL ANG1005 PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 8. GLOBAL BT1718 PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 9. GLOBAL CBX-12 PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 10. GLOBAL PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
• 11. NORTH AMERICAN PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
• 12. NORTH AMERICAN PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
• 13. NORTH AMERICAN PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
• 14. EUROPEAN PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
• 15. EUROPEAN PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
• 16. EUROPEAN PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
• 17. ASIA-PACIFIC PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
• 18. ASIA-PACIFIC PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
• 19. ASIA-PACIFIC PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
• 20. REST OF THE WORLD PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY TYPE, 2022-2030 ($ MILLION)
• 21. REST OF THE WORLD PEPTIDE DRUG CONJUGATES MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)

LIST OF FIGURES

• 1. GLOBAL PEPTIDE DRUG CONJUGATES MARKET SHARE BY TYPE, 2022 VS 2030 (%)
• 2. GLOBAL DIAGNOSTIC PEPTIDE DRUG CONJUGATES MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 3. GLOBAL THERAPEUTIC PEPTIDE DRUG CONJUGATES MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 4. GLOBAL PEPTIDE DRUG CONJUGATES MARKET SHARE BY PRODUCT, 2022 VS 2030 (%)
• 5. GLOBAL MELFLUFEN PEPTIDE DRUG CONJUGATES MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 6. GLOBAL LUTETIUM PEPTIDE DRUG CONJUGATES MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 7. GLOBAL ANG1005 PEPTIDE DRUG CONJUGATES MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 8. GLOBAL BT1718 PEPTIDE DRUG CONJUGATES MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 9. GLOBAL CBX-12 PEPTIDE DRUG CONJUGATES MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 10. GLOBAL PEPTIDE DRUG CONJUGATES MARKET SHARE BY REGION, 2022 VS 2030 (%)
• 11. US PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
• 12. CANADA PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
• 13. UK PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
• 14. FRANCE PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
• 15. GERMANY PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
• 16. ITALY PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
• 17. SPAIN PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
• 18. REST OF EUROPE PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
• 19. INDIA PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
• 20. CHINA PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
• 21. JAPAN PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
• 22. SOUTH KOREA PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
• 23. REST OF ASIA-PACIFIC PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)
• 24. REST OF THE WORLD PEPTIDE DRUG CONJUGATES MARKET SIZE, 2022-2030 ($ MILLION)